hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_01131
Confidence: High
Proteins| Genename | Protein Name | Links |
|---|---|---|
| CDKN2A | Tumor suppressor ARF (Alternative reading frame) (ARF) (Cyclin-dependent kinase inhibitor 2A) (p14ARF) | UniProt NCBI |
| CDKN2B | Cyclin-dependent kinase 4 inhibitor B (Multiple tumor suppressor 2) (MTS-2) (p14-INK4b) (p15-INK4b) (p15INK4B) | UniProt NCBI |
| CDKN2C | Cyclin-dependent kinase 4 inhibitor C (Cyclin-dependent kinase 6 inhibitor) (p18-INK4c) (p18-INK6) | UniProt NCBI |
| CDK4 | Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3) | UniProt NCBI |
| OGFRL1 | Opioid growth factor receptor-like protein 1 | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| WP:WP3998 | 1.22392764803e-08 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Prader-Willi and Angelman Syndrome |
| REAC:R-HSA-2559585 | 1.31129440131e-08 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Oncogene Induced Senescence |
| REAC:R-HSA-69231 | 4.07937169667e-08 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cyclin D associated events in G1 |
| REAC:R-HSA-69236 | 4.07937169667e-08 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | G1 Phase |
| WP:WP45 | 5.36500674309e-08 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | G1 to S cell cycle control |
| WP:WP2261 | 1.57372166421e-07 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Signaling Pathways in Glioblastoma |
| WP:WP179 | 6.43063247751e-07 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cell Cycle |
| KEGG:04110 | 9.48333739363e-07 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cell cycle |
| HP:0002894 | 1.28898017461e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Neoplasm of the pancreas |
| REAC:R-HSA-2559582 | 1.80427312053e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Senescence-Associated Secretory Phenotype (SASP) |
| KEGG:04934 | 1.81933554316e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cushing syndrome |
| HP:0012334 | 2.67504688957e-06 | 0.6 | CDKN2B CDKN2C CDKN2A | Extrahepatic cholestasis |
| REAC:R-HSA-2559580 | 3.18738411547e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Oxidative Stress Induced Senescence |
| REAC:R-HSA-453279 | 6.76665795869e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Mitotic G1-G1/S phases |
| KEGG:05166 | 6.99700274835e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Human T-cell leukemia virus 1 infection |
| HP:0100641 | 7.62845613622e-06 | 0.6 | CDKN2B CDKN2C CDKN2A | Neoplasm of the adrenal cortex |
| GO:0016538 | 8.04174090024e-06 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | cyclin-dependent protein serine/threonine kinase regulator activity |
| REAC:R-HSA-9632697 | 1.34977069275e-05 | 0.4 | CDK4 CDKN2A | Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 |
| REAC:R-HSA-9630791 | 1.34977069275e-05 | 0.4 | CDK4 CDKN2A | Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 |
| REAC:R-HSA-2559583 | 1.82260482774e-05 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cellular Senescence |
| CORUM:1642 | 2.0123342217e-05 | 0.4 | CDK4 CDKN2A | p16-cyclin D2-CDK4 complex |
| HP:0008069 | 2.66642116579e-05 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Neoplasm of the skin |
| HP:0100631 | 3.41219105177e-05 | 0.6 | CDKN2B CDKN2C CDKN2A | Neoplasm of the adrenal gland |
| REAC:R-HSA-9632693 | 4.04876825444e-05 | 0.4 | CDK4 CDKN2A | Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects |
| REAC:R-HSA-9632700 | 4.04876825444e-05 | 0.4 | CDK4 CDKN2A | Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 |
| REAC:R-HSA-9630750 | 4.04876825444e-05 | 0.4 | CDK4 CDKN2A | Evasion of Oncogene Induced Senescence Due to p16INK4A Defects |
| REAC:R-HSA-9630794 | 4.04876825444e-05 | 0.4 | CDK4 CDKN2A | Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 |
| REAC:R-HSA-9630747 | 4.04876825444e-05 | 0.4 | CDK4 CDKN2A | Diseases of Cellular Senescence |
| HP:0007378 | 6.27577332437e-05 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Neoplasm of the gastrointestinal tract |
| GO:0004861 | 7.62415024416e-05 | 0.6 | CDKN2B CDKN2C CDKN2A | cyclin-dependent protein serine/threonine kinase inhibitor activity |
| HP:0001480 | 9.94251439245e-05 | 0.6 | CDKN2B CDKN2A CDK4 | Freckling |
| KEGG:01522 | 0.000100724565592 | 0.6 | CDK4 CDKN2C CDKN2A | Endocrine resistance |
| HP:0001732 | 0.000115895357239 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Abnormality of the pancreas |
| HP:0011792 | 0.000156459557756 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Neoplasm by histology |
| WP:WP2877 | 0.000221479362247 | 0.6 | CDKN2B CDKN2C CDKN2A | Vitamin D Receptor Pathway |
| GO:2000134 | 0.000270299027917 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | negative regulation of G1/S transition of mitotic cell cycle |
| HP:0006753 | 0.000272465709143 | 0.6 | CDKN2B CDKN2A CDK4 | Neoplasm of the stomach |
| GO:1902807 | 0.000283155128059 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | negative regulation of cell cycle G1/S phase transition |
| HP:0002861 | 0.000287298458388 | 0.6 | CDKN2B CDKN2A CDK4 | Melanoma |
| REAC:R-HSA-2262752 | 0.000402506828977 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cellular responses to stress |
| KEGG:04218 | 0.000424294655338 | 0.6 | CDKN2B CDKN2A CDK4 | Cellular senescence |
| HP:0008291 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Pituitary corticotropic cell adenoma |
| HP:0030687 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Abnormal glucagon level |
| HP:0030688 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Increased glucagon level |
| HP:0100522 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Thymoma |
| HP:0011761 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Pituitary null cell adenoma |
| HP:0012197 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Insulinoma |
| HP:0030404 | 0.00046457916755 | 0.4 | CDKN2B CDKN2C | Glucagonoma |
| HP:0011732 | 0.000487295745405 | 0.6 | CDKN2B CDKN2C CDKN2A | Abnormality of adrenal morphology |
| HP:0100013 | 0.000578226462924 | 0.6 | CDKN2B CDKN2A CDK4 | Neoplasm of the breast |
| HP:0030405 | 0.000696775152219 | 0.4 | CDKN2B CDKN2C | Pancreatic endocrine tumor |
| HP:0008208 | 0.000696775152219 | 0.4 | CDKN2B CDKN2C | Parathyroid hyperplasia |
| HP:0008261 | 0.000696775152219 | 0.4 | CDKN2B CDKN2C | Pancreatic islet cell adenoma |
| REAC:R-HSA-8953897 | 0.00083024651806 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cellular responses to external stimuli |
| KEGG:05203 | 0.000925161775741 | 0.6 | CDKN2B CDKN2A CDK4 | Viral carcinogenesis |
| GO:2000045 | 0.000962610785502 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | regulation of G1/S transition of mitotic cell cycle |
| HP:0007449 | 0.00097535418756 | 0.4 | CDKN2B CDKN2C | Confetti-like hypopigmented macules |
| HP:0006767 | 0.00097535418756 | 0.4 | CDKN2B CDKN2C | Pituitary prolactin cell adenoma |
| HP:0011760 | 0.00097535418756 | 0.4 | CDKN2B CDKN2C | Pituitary growth hormone cell adenoma |
| HP:0100521 | 0.00097535418756 | 0.4 | CDKN2B CDKN2C | Neoplasm of the thymus |
| REAC:R-HSA-69278 | 0.00103692271301 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cell Cycle, Mitotic |
| HP:0100568 | 0.00124354263601 | 0.6 | CDKN2B CDKN2C CDKN2A | Neoplasm of the endocrine system |
| HP:0012030 | 0.00130029756695 | 0.4 | CDKN2B CDKN2C | Increased urinary cortisol level |
| HP:0012029 | 0.00130029756695 | 0.4 | CDKN2B CDKN2C | Abnormal urine hormone level |
| HP:0008256 | 0.00130029756695 | 0.4 | CDKN2B CDKN2C | Adrenocortical adenoma |
| HP:0002044 | 0.00130029756695 | 0.4 | CDKN2B CDKN2C | Zollinger-Ellison syndrome |
| GO:1902806 | 0.00137615171612 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | regulation of cell cycle G1/S phase transition |
| HP:0000488 | 0.00141044232307 | 0.6 | CDKN2B CDKN2A CDK4 | Retinopathy |
| WP:WP4204 | 0.00144719807027 | 0.4 | CDK4 CDKN2A | Tumor suppressor activity of SMARCB1 |
| HP:0003764 | 0.00149920031601 | 0.6 | CDKN2B CDKN2A CDK4 | Nevus |
| GO:0019887 | 0.0016512304967 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | protein kinase regulator activity |
| HP:0100570 | 0.00167158658755 | 0.4 | CDKN2B CDKN2C | Carcinoid tumor |
| HP:0100242 | 0.00178757045499 | 0.6 | CDKN2B CDKN2C CDKN2A | Sarcoma |
| HP:0008283 | 0.00208920255027 | 0.4 | CDKN2B CDKN2C | Fasting hyperinsulinemia |
| HP:0006744 | 0.00208920255027 | 0.4 | CDKN2B CDKN2C | Adrenocortical carcinoma |
| HP:0001031 | 0.00208920255027 | 0.4 | CDKN2B CDKN2C | Subcutaneous lipoma |
| WP:WP2828 | 0.00209425195703 | 0.4 | CDK4 CDKN2A | Bladder Cancer |
| HP:0012091 | 0.00211059325497 | 0.6 | CDKN2B CDKN2C CDKN2A | Abnormality of pancreas physiology |
| REAC:R-HSA-1640170 | 0.0021256129161 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Cell Cycle |
| GO:0030291 | 0.00235581550516 | 0.6 | CDKN2B CDKN2C CDKN2A | protein serine/threonine kinase inhibitor activity |
| HP:0000958 | 0.00253383203522 | 0.6 | CDKN2B CDKN2A CDK4 | Dry skin |
| HP:0020073 | 0.0025531267598 | 0.4 | CDKN2B CDKN2C | Hypopigmented macule |
| KEGG:05219 | 0.00284609034939 | 0.4 | CDK4 CDKN2A | Bladder cancer |
| WP:WP1971 | 0.00299893680898 | 0.4 | CDKN2B CDK4 | Integrated Cancer Pathway |
| GO:0019207 | 0.00302325172609 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | kinase regulator activity |
| HP:0012056 | 0.0030633405246 | 0.4 | CDK4 CDKN2A | Cutaneous melanoma |
| HP:0100763 | 0.0031998636837 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Abnormality of the lymphatic system |
| HP:0003118 | 0.00361982515692 | 0.4 | CDKN2B CDKN2C | Increased circulating cortisol level |
| HP:0004375 | 0.00422237396976 | 0.6 | CDKN2B CDKN2C CDKN2A | Neoplasm of the nervous system |
| HP:0002897 | 0.00487153229182 | 0.4 | CDKN2B CDKN2C | Parathyroid adenoma |
| HP:0100733 | 0.00487153229182 | 0.4 | CDKN2B CDKN2C | Neoplasm of the parathyroid gland |
| HP:0000834 | 0.00498434077123 | 0.6 | CDKN2B CDKN2C CDKN2A | Abnormality of the adrenal glands |
| HP:0000854 | 0.00556671743772 | 0.4 | CDKN2B CDKN2C | Thyroid adenoma |
| HP:0003165 | 0.00556671743772 | 0.4 | CDKN2B CDKN2C | Elevated circulating parathyroid hormone level |
| GO:0007050 | 0.00621878427592 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | cell cycle arrest |
| HP:0000845 | 0.00709565752293 | 0.4 | CDKN2B CDKN2C | Growth hormone excess |
| HP:0011766 | 0.00709565752293 | 0.4 | CDKN2B CDKN2C | Abnormality of the parathyroid morphology |
| GO:1901991 | 0.00749792730182 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | negative regulation of mitotic cell cycle phase transition |
| HP:0000843 | 0.00792937512816 | 0.4 | CDKN2B CDKN2C | Hyperparathyroidism |
| GO:0000082 | 0.00796512695553 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | G1/S transition of mitotic cell cycle |
| WP:WP4255 | 0.00799132765459 | 0.4 | CDK4 CDKN2A | Non-small cell lung cancer |
| KEGG:05218 | 0.00805388520034 | 0.4 | CDK4 CDKN2A | Melanoma |
| HP:0011355 | 0.00846318146995 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Localized skin lesion |
| KEGG:05223 | 0.00858395707223 | 0.4 | CDK4 CDKN2A | Non-small cell lung cancer |
| KEGG:04115 | 0.00858395707223 | 0.4 | CDK4 CDKN2A | p53 signaling pathway |
| HP:0004398 | 0.00880923289202 | 0.4 | CDKN2B CDKN2C | Peptic ulcer |
| HP:0011793 | 0.00894528033019 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Neoplasm by anatomical site |
| HP:0012719 | 0.00961956088686 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Functional abnormality of the gastrointestinal tract |
| GO:1901988 | 0.00968108110961 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | negative regulation of cell cycle phase transition |
| KEGG:05214 | 0.00969431019543 | 0.4 | CDK4 CDKN2A | Glioma |
| GO:0044843 | 0.0100550100183 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | cell cycle G1/S phase transition |
| HP:0001396 | 0.0105012068371 | 0.6 | CDKN2B CDKN2C CDKN2A | Cholestasis |
| KEGG:05212 | 0.0105709544625 | 0.4 | CDK4 CDKN2A | Pancreatic cancer |
| HP:0002664 | 0.0106387322837 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Neoplasm |
| HP:0000825 | 0.0107072942689 | 0.4 | CDKN2B CDKN2C | Hyperinsulinemic hypoglycemia |
| HP:0010615 | 0.0107072942689 | 0.4 | CDKN2B CDKN2C | Angiofibromas |
| HP:0006476 | 0.0107072942689 | 0.4 | CDKN2B CDKN2C | Abnormality of the pancreatic islet cells |
| HP:0100633 | 0.0107072942689 | 0.4 | CDKN2B CDKN2C | Esophagitis |
| WP:WP4263 | 0.0112409645576 | 0.4 | CDK4 CDKN2A | Pancreatic adenocarcinoma pathway |
| KEGG:05220 | 0.0114851584748 | 0.4 | CDK4 CDKN2A | Chronic myeloid leukemia |
| HP:0012093 | 0.011725460578 | 0.4 | CDKN2B CDKN2C | Abnormality of endocrine pancreas physiology |
| HP:0002027 | 0.0131698060475 | 0.6 | CDKN2B CDKN2C CDKN2A | Abdominal pain |
| HP:0002071 | 0.0131698060475 | 0.6 | CDKN2B CDKN2A CDK4 | Abnormality of extrapyramidal motor function |
| KEGG:05200 | 0.0137388951306 | 0.6 | CDKN2B CDKN2A CDK4 | Pathways in cancer |
| WP:WP4658 | 0.0147251965341 | 0.4 | CDKN2B CDK4 | Small cell lung cancer |
| HP:0002717 | 0.0150562782431 | 0.4 | CDKN2B CDKN2C | Adrenal overactivity |
| HP:0100634 | 0.0162585949147 | 0.4 | CDKN2B CDKN2C | Neuroendocrine neoplasm |
| HP:0002893 | 0.0162585949147 | 0.4 | CDKN2B CDKN2C | Pituitary adenoma |
| HP:0032148 | 0.0175069025895 | 0.4 | CDKN2B CDKN2C | Episodic pain |
| HP:0002574 | 0.0175069025895 | 0.4 | CDKN2B CDKN2C | Episodic abdominal pain |
| KEGG:05222 | 0.0177565608839 | 0.4 | CDKN2B CDK4 | Small cell lung cancer |
| GO:0004860 | 0.0199719657189 | 0.6 | CDKN2B CDKN2C CDKN2A | protein kinase inhibitor activity |
| HP:0100530 | 0.0201414164419 | 0.4 | CDKN2B CDKN2C | Abnormal calcium-phosphate regulating hormone level |
| HP:0011731 | 0.0201414164419 | 0.4 | CDKN2B CDKN2C | Abnormality of circulating cortisol level |
| HP:0012111 | 0.0215275853758 | 0.4 | CDKN2B CDKN2C | Abnormality of circulating glucocorticoid level |
| HP:0002014 | 0.0215839586173 | 0.6 | CDKN2B CDKN2C CDKN2A | Diarrhea |
| HP:0001012 | 0.0244376541782 | 0.4 | CDKN2B CDKN2C | Multiple lipomas |
| HP:0040277 | 0.0244376541782 | 0.4 | CDKN2B CDKN2C | Neoplasm of the pituitary gland |
| HP:0011750 | 0.0244376541782 | 0.4 | CDKN2B CDKN2C | Neoplasm of the anterior pituitary |
| GO:0019210 | 0.0250406933376 | 0.6 | CDKN2B CDKN2C CDKN2A | kinase inhibitor activity |
| GO:0045930 | 0.0252719643298 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | negative regulation of mitotic cell cycle |
| HP:0012718 | 0.0260448941493 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Morphological abnormality of the gastrointestinal tract |
| HP:0025033 | 0.0260448941493 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Abnormality of digestive system morphology |
| HP:0004297 | 0.0282751952306 | 0.6 | CDKN2B CDKN2C CDKN2A | Abnormality of the biliary system |
| HP:0012031 | 0.0325153883173 | 0.4 | CDKN2B CDKN2C | Lipomatous tumor |
| HP:0200013 | 0.0325153883173 | 0.4 | CDKN2B CDKN2C | Neoplasm of fatty tissue |
| GO:0010948 | 0.0327910140884 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | negative regulation of cell cycle process |
| HP:0000769 | 0.0333025936722 | 0.6 | CDKN2B CDKN2A CDK4 | Abnormality of the breast |
| HP:0031093 | 0.0333025936722 | 0.6 | CDKN2B CDKN2A CDK4 | Abnormal breast morphology |
| HP:0001001 | 0.0379116132621 | 0.4 | CDKN2B CDKN2C | Abnormality of subcutaneous fat tissue |
| HP:0003072 | 0.0379116132621 | 0.4 | CDKN2B CDKN2C | Hypercalcemia |
| HP:0100007 | 0.0379116132621 | 0.4 | CDKN2B CDKN2C | Neoplasm of the peripheral nervous system |
| HP:0002012 | 0.038603375935 | 0.8 | CDK4 CDKN2B CDKN2C CDKN2A | Abnormality of the abdominal organs |
| HP:0000777 | 0.0398018408038 | 0.4 | CDKN2B CDKN2C | Abnormality of the thymus |
| CORUM:5287 | 0.0499494897235 | 0.2 | CDK4 | CCND1-CDK4 complex |
| CORUM:5107 | 0.0499494897235 | 0.2 | CDK4 | p34(SEI-1)-CDK4-CyclinD2 complex |
| CORUM:3086 | 0.0499494897235 | 0.2 | CDK4 | CCND3-CDK4 complex |
| CORUM:3085 | 0.0499494897235 | 0.2 | CDK4 | CCND2-CDK4 complex |
| CORUM:3084 | 0.0499494897235 | 0.2 | CDK4 | CCND1-CDK4 complex |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| CDKN2B | CDK4 | 1.0 | 0.949 | hein_WMM bioplex (CDK4) bioplex_WMM hein (CDK4) |
| CDKN2A | CDK4 | 0.974 | 0.886 | hein_WMM bioplex (CDK4) bioplex_WMM youn_WMM hein (CDK4) gupta_WMM |
| CDKN2C | CDK4 | 0.654 | 0.692 | bioplex (CDK4,CDKN2C) bioplex_WMM |
| CDK4 | OGFRL1 | 0.65 | 0.689 | bioplex (CDK4) bioplex_WMM |
| CDKN2C | CDKN2A | 0.011 | 0.139 | bioplex_WMM WMM_only |
| CDKN2B | CDKN2A | 0.01 | 0.137 | hein_WMM bioplex_WMM WMM_only |
| CDKN2B | CDKN2C | 0.01 | 0.1 | bioplex_WMM WMM_only |
| CDKN2B | OGFRL1 | 0.009 | 0.108 | bioplex_WMM WMM_only |
| CDKN2A | OGFRL1 | 0.008 | 0.085 | bioplex_WMM WMM_only |
| CDKN2C | OGFRL1 | 0.008 | 0.085 | bioplex_WMM WMM_only |
Images
Click to enlarge
Complex HuMAP2_01131 has an average edge precision of 0.387 which is ranked 3456 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| CDKN2A | HuMAP2_01131 HuMAP2_02676 HuMAP2_03636 HuMAP2_06643 |
| CDKN2B | HuMAP2_01131 HuMAP2_01198 HuMAP2_03365 HuMAP2_06643 |
| CDKN2C | HuMAP2_01131 HuMAP2_01816 HuMAP2_02228 HuMAP2_02676 HuMAP2_03854 HuMAP2_05212 HuMAP2_06056 HuMAP2_06643 |
| CDK4 | HuMAP2_01131 HuMAP2_02676 HuMAP2_03636 HuMAP2_06643 |
| OGFRL1 | HuMAP2_01131 HuMAP2_02676 HuMAP2_06643 |